HK Stock Market Move | Huaqin Co.,Ltd. (03296) rises over 10%; Q3 non-GAAP net profit attributable to parent hits a new quarterly high; Super Node revenue reaches RMB6.2 billion.
Huaqin Co.,Ltd. (03296) share price moved higher, rising 9.71% as of press time to HK$55.95, with turnover of HK$77.9391 million.
Huaqin Co.,Ltd. (03296) shares moved higher, rising 9.71% as of press time to HK$55.95, with turnover of HK$77.9391 million.
On the news front, Huaqin Co.,Ltd. reported third-quarter operating revenue of RMB72.295 billion, up 60.86% year on year; net profit attributable to parent of RMB1.324 billion, up 9.43% year on year; and non-GAAP net profit attributable to parent of RMB1.187 billion, up 22.39% year on year, a new quarterly record high. In the third quarter, the company's data center business revenue reached RMB22.5 billion, up 228% year on year, of which Super Node products have achieved volume delivery, with revenue reaching RMB6.2 billion, marking that Super Node has officially entered the "from 0 to 1" mass production stage from early validation, and the company expects continued volume growth in Q4.
Related Articles

HENLIUS (02696): Phase 1 clinical trial of HLX109 injection (an anti-IL1RAP monoclonal antibody) for the treatment of generalized pustular psoriasis approved to commence in Australia

Shaanxi Kanghui Pharmaceutical (603139.SH) plans to contribute RMB35 million to establish a subsidiary, Wanhuashan Pharmaceutical.

Zhonghong Pulin Medical Products (300981.SZ): Subsidiary Kelun Medical Devices is proposed as a selected candidate in a centralized volume-based procurement project.
HENLIUS (02696): Phase 1 clinical trial of HLX109 injection (an anti-IL1RAP monoclonal antibody) for the treatment of generalized pustular psoriasis approved to commence in Australia

Shaanxi Kanghui Pharmaceutical (603139.SH) plans to contribute RMB35 million to establish a subsidiary, Wanhuashan Pharmaceutical.

Zhonghong Pulin Medical Products (300981.SZ): Subsidiary Kelun Medical Devices is proposed as a selected candidate in a centralized volume-based procurement project.






